Amber Martin

Amber Martin is a seasoned Senior Research Associate currently employed at BioNTech SE since February 2023, with prior experience at SQZ Biotechnologies from November 2020 to January 2023. At SQZ Biotechnologies, Amber was instrumental in developing the clinical product SQZ-eAPC-HPV, focusing on enhanced Antigen Presenting Cells. Amber's expertise includes demonstrating the efficacy of eAPCs in priming anti-tumor T cells through advanced techniques such as flow cytometry and ex vivo assays. Amber's research background includes a position as a Research Assistant at Purdue University, studying actin-binding proteins in mouse oocytes, and previous roles at Thiel College, examining the immune response of human neutrophils to infections. Amber holds a Master of Science in Biochemistry and Molecular Biology from Johns Hopkins Bloomberg School of Public Health, a Bachelor of Science in Biology from Thiel College, and a certificate in Fundamentals of Immunology from Harvard Medical School.